Trident Lifeline Ltd
Incorporated in 2014, Trident Lifeline Ltd manufactures and sells pharmaceuticals
products[1]
- Market Cap ₹ 325 Cr.
- Current Price ₹ 273
- High / Low ₹ 328 / 230
- Stock P/E 16.6
- Book Value ₹ 83.0
- Dividend Yield 0.00 %
- ROCE 26.1 %
- ROE 22.0 %
- Face Value ₹ 10.0
Pros
- Company is expected to give good quarter
- Company has delivered good profit growth of 95.7% CAGR over last 5 years
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has high debtors of 177 days.
- Promoter holding has decreased over last 3 years: -7.45%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|
| 5 | 10 | 22 | 32 | 45 | 68 | 102 | 110 | |
| 5 | 8 | 19 | 25 | 36 | 50 | 78 | 83 | |
| Operating Profit | -0 | 1 | 3 | 6 | 9 | 18 | 24 | 27 |
| OPM % | -5% | 13% | 12% | 20% | 20% | 26% | 24% | 24% |
| 0 | 0 | 1 | 1 | 2 | 3 | 4 | 4 | |
| Interest | 1 | 0 | 0 | 0 | 1 | 1 | 2 | 2 |
| Depreciation | 0 | 0 | 0 | 0 | 1 | 2 | 2 | 2 |
| Profit before tax | -1 | 1 | 3 | 7 | 10 | 18 | 25 | 27 |
| Tax % | -26% | 26% | -32% | 9% | 28% | 27% | 28% | |
| -1 | 1 | 4 | 6 | 7 | 13 | 18 | 20 | |
| EPS in Rs | -2.58 | 1.26 | 4.94 | 5.23 | 6.12 | 11.35 | 15.16 | 16.57 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 60% |
| 3 Years: | 48% |
| TTM: | 53% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 96% |
| 3 Years: | 44% |
| TTM: | 38% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 7% |
| 1 Year: | -1% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 22% |
| 3 Years: | 20% |
| Last Year: | 22% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 3 | 5 | 8 | 12 | 12 | 12 | 12 |
| Reserves | -6 | -5 | -3 | 34 | 41 | 54 | 87 |
| 6 | 5 | 2 | 3 | 6 | 15 | 25 | |
| 3 | 7 | 7 | 7 | 14 | 17 | 36 | |
| Total Liabilities | 6 | 11 | 14 | 56 | 73 | 98 | 159 |
| 1 | 1 | 1 | 3 | 8 | 15 | 29 | |
| CWIP | 0 | 0 | 0 | 0 | 4 | 1 | 0 |
| Investments | 0 | 0 | 0 | 4 | 4 | 12 | 20 |
| 6 | 10 | 12 | 49 | 57 | 70 | 111 | |
| Total Assets | 6 | 11 | 14 | 56 | 73 | 98 | 159 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| -1 | 1 | -0 | -17 | 1 | -3 | 8 | |
| -0 | -1 | -0 | -6 | -11 | -8 | -20 | |
| 1 | -1 | 1 | 36 | 2 | 7 | 14 | |
| Net Cash Flow | 0 | -0 | 0 | 14 | -8 | -4 | 2 |
| Free Cash Flow | -1 | 1 | -1 | -19 | -8 | -9 | -7 |
| CFO/OP | 219% | 118% | -7% | -256% | 37% | 4% | 57% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 97 | 24 | 83 | 140 | 112 | 110 | 177 |
| Inventory Days | 104 | 349 | 95 | 129 | 137 | 167 | 136 |
| Days Payable | 202 | 266 | 134 | 87 | 94 | 97 | 153 |
| Cash Conversion Cycle | -1 | 107 | 44 | 183 | 155 | 180 | 160 |
| Working Capital Days | -12 | 12 | 49 | 274 | 246 | 226 | 192 |
| ROCE % | 34% | 55% | 25% | 19% | 28% | 26% |
Insights
In beta| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Africa Revenue Share % |
|
||||||
| Export Revenue Share (Direct + Merchant Exports) % |
|||||||
| Tablet Revenue Share % |
|||||||
| Products in Portfolio count |
|||||||
| Consolidated Manufacturing Capacity - Tablets Million per Month |
|||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement Under Regulation 30(LODR)-Trident Lifeline Limited Featured In India Pharma Outlook Magazine
- Trident Lifeline featured in India Pharma Outlook magazine on August 22, 2026.
-
Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirement) Regulations, 2015- Intimation Of Award
- Trident Lifeline won Fastest Growing SMEs award at Gujarat Top 50 SME Awards on August 20, 2026.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
- Company held analyst/institutional investor meetings in Surat on August 20, 2026.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
- Pursuant to the requirements of Regulation 30 of the Securities Exchange Board of India (Listing obligation and Disclosure Requirements) Regulations, 2015, we would like to …
-
Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirement) Regulations, 2015- Intimation Of Award
- Trident Lifeline selected for ‘Fastest Growing SMEs’ award; presentation on 20 August 2026 in Ahmedabad.
Concalls
-
Aug 2026TranscriptAI SummaryPPT
-
May 2026TranscriptAI SummaryPPT
-
Jan 2026TranscriptAI SummaryPPT
-
Nov 2025TranscriptAI SummaryPPT
-
Jul 2025TranscriptAI SummaryPPT
-
Oct 2024TranscriptAI SummaryPPT
-
Jul 2024TranscriptAI SummaryPPT
-
May 2024TranscriptAI SummaryPPT
-
Nov 2023TranscriptAI SummaryPPT
-
Jul 2023TranscriptAI SummaryPPT
-
May 2023TranscriptAI SummaryPPT
-
Jan 2023TranscriptAI SummaryPPT
Business Overview:[1]
TLL is a Surat-based pharmaceutical and healthcare-products company. It began as an export-oriented formulations company using third-party and loan-licence manufacturing. It is now evolving into a vertically integrated healthcare-manufacturing platform through its own and subsidiary facilities.